DOGWOOD THERAPEUTICS

Dogwood Therapeutics Announces First Quarter 2025 Financial Results

08 May 2025 06:00:00 By Nasdaq GlobeNewswire

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

11 Apr 2025 06:15:00 By Nasdaq GlobeNewswire

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

03 Apr 2025 06:00:00 By Nasdaq GlobeNewswire

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

31 Mar 2025 12:45:53 By Nasdaq GlobeNewswire

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

18 Mar 2025 05:45:00 By Nasdaq GlobeNewswire

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

13 Mar 2025 06:00:00 By Nasdaq GlobeNewswire

Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward

12 Mar 2025 05:30:00 By Nasdaq GlobeNewswire

Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025

21 Jan 2025 06:15:00 By Nasdaq GlobeNewswire

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

18 Nov 2024 05:45:00 By Nasdaq GlobeNewswire

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

07 Nov 2024 04:05:00 By Nasdaq GlobeNewswire

Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024

31 Oct 2024 06:15:00 By Nasdaq GlobeNewswire

Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

30 Oct 2024 06:15:00 By Nasdaq GlobeNewswire